A study to compare the effects of two doses of oral drug isotretinoin in the treatment of pimples

A comparative study of daily low dose and intermittent dose of oral isotretinoin in patients of grade 2 acne vulgaris - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/09/057402

Enrollment

Registered

2023-09-11

Start date

Unknown

Completion date

Unknown

Last updated

2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L700- Acne vulgaris

Interventions

Intervention1: 20 mg oral Isotretinoin: To be prescribed on alternate days for 3 months Control Intervention1: 30 mg oral Isotretinoin: To be prescribed for 1 week in a month for 3 months

Eligibility

Inclusion criteria

Inclusion criteria: Patients aged 18 years and above and diagnosed with grade 2 acne vulgaris after clinical assessment who are isotretinoin naive and who have not responded to previous topical anti acne agents or oral antibiotics

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women 2. Deranged liver function 3. Deranged lipid profile 4. Concomitant oral antibiotics

Design outcomes

Primary

Measure	Time frame
The primary outcome of the study will be the comparison of efficacy of low dose daily & intermittent dose oral isotretinoin regimens in patients of grade 2 acne vulgaris Timepoint: Assessment at 3 & 6 months	—

Secondary

Measure	Time frame
The secondary outcome will be the comparision of side effect profile & patient satisfaction of the two regimensTimepoint: Assessment at 3 & 6 months	—

Countries

India

Contacts

Public ContactDr. Shikha Verma

North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences

shikha.b.thakur@gmail.com9774168689

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026